A drop in the number of young women infected with the two strains of human papillomavirus (HPV) most likely to cause cervical cancer occurred in England after the 2008 launch of a national vaccination program.More >>
A sharp drop in the number of young women infected with the two strains of human papillomavirus (HPV) most likely to cause cervical cancer occurred in England after the 2008 launch of a national vaccination program.More >>
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Star Scientific, Inc.
GLEN ALLEN, Va., Feb. 12, 2014 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) announced today that Theodore Jenkins has joined the Company as Vice President, Corporate Strategy and Development. Mr. Jenkins will be working directly with Dr. Michael Mullan, Chairman and Chief Executive Officer, to enhance, broaden, and clarify the Company's institutional investment and corporate development efforts.
Mr. Jenkins' experience encompasses an extensive 18-year Wall Street career as an institutional capital markets professional, working at top-tier, global and regional investment banks. He has a proven history of generating significant client revenue and communicating differentiated value with some of the largest investment managers in the United States. He brings valuable insight, aptitude, and knowledge from working with a wide spectrum of biotech and pharmaceutical healthcare disciplines derived from his close interaction with numerous companies in the sector and with specialist healthcare finance professionals. As a result, Mr. Jenkins has an abundance of relationships across the institutional and corporate banking investment community.
Dr. Mullan commented, "I first met Ted a number of years ago and have been impressed with his business, technical, and scientific acumen, as it applies to the research and development strategy of the Company. His tireless enthusiasm and experience will be an invaluable asset for us."
Mr. Jenkins' background includes nine years as a US Navy Officer serving as an aviator, flying F-14a tactical fighter aircraft and finishing his tour as a professional development instructor teaching midshipmen at the US Naval Academy in Annapolis, Maryland. He has a Master's of Science in Business from The Johns Hopkins University, and an undergraduate degree in International Studies from Washington College in Chestertown, Maryland.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2012 and our quarterly reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013, and September 30, 2013. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. Through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, cosmetic products, and the development of other nutraceuticals and pharmaceuticals. The company also continues to pursue the licensing of the technology behind its proprietary StarCured® curing process and its related products.
Contact: Talhia T. Tuck Vice President, Communications and Investor Relations Star Scientific, Inc. (202)887-5100 email@example.com